Investor Contact

Media & Investor Relations:
Troy Wichterman 
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc. 
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.

Press Releases

BioLife Solutions to Present at Third Annual Marcum MicroCap Conference
PR Newswire
BOTHELL, Wash.

BOTHELL, Wash., May 12, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that management will present at the Third Annual Marcum MicroCap Conference in New York City on May 29, 2014 at the Grand Hyatt New York. Since 2012, the Marcum conference has introduced investors to promising undiscovered companies with a market capitalization of under $500 million. As part of the conference, BioLife will participate in one-on-one meetings with investors and other companies.

Mike Rice, BioLife's President & CEO, said, "The Marcum conference is a great forum for companies like BioLife. I look forward to presenting an investment thesis based on our potential growth as an embedded life science tools provider. Our strategic markets of biobanking, drug discovery, and regenerative medicine have significant unmet needs in the biopreservation and transportation of cells and tissues used in research and clinical applications. Our tools portfolio has demonstrated great success in extending yield and viability of biologics and we are well configured to participate in the growth of key vertical markets." 

BioLife will present growth opportunities for its proprietary, clinical grade biopreservation media products including CryoStor® freeze media and HypoThermosol® shipping and storage medium, specialty contract manufacturing services, and biologistexsm cloud-based monitoring and management portal for EVO™ smart, controlled temperature shipping containers for cells and tissues.

Presentation time and details:

  • Location: Grand Hyatt New York (109 E 42nd Street, New York, NY 10017)
  • Date: May 29, 2014
  • Time: 1:30PM2:00PM ET
  • Room: Morosco

The conference will feature the following presentation tracks:

  • Healthcare and Life Sciences
  • Energy and Natural Resources
  • Retail and Consumer Products
  • Industrials
  • Technology, Media and Telecommunications
  • Financial and Asset Management Services

To schedule a one-on-one meeting with management, please contact Daphne Taylor by phone, (425) 402-1400, or email at dtaylor@biolifesolutions.com.

About the Marcum MicroCap Conference

The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization. Launched in 2012, the annual Marcum MicroCap Conference features presentations by CEOs and CFOs from promising high-growth companies, the top picks by some of the most astute analysts following small caps, and thoughtful commentary on successful investment strategies and sectors. This invitation-only event attracts top fund managers and qualified high net worth investors who focus on small cap equities. One-on-one meetings are available for company management teams and qualified investors.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning our potential revenue growth and market expansion. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations



Daphne Taylor



Senior Vice President, Chief Financial Officer



(425) 402-1400



dtaylor@biolifesolutions.com






SOURCE BioLife Solutions, Inc.